C
Caren Chapinski
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 3
Citations - 1145
Caren Chapinski is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & PI3K/AKT/mTOR pathway. The author has an hindex of 3, co-authored 3 publications receiving 1020 citations.
Papers
More filters
Journal ArticleDOI
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver,Caren Chapinski,John Wongvipat,Haley Hieronymus,Yu Chen,Sarat Chandarlapaty,Vivek K. Arora,Carl Le,Jason A. Koutcher,Howard I. Scher,Peter T. Scardino,Neal Rosen,Charles L. Sawyers +12 more
TL;DR: Combined pharmacologic inhibition of PI3K and AR signaling caused near-complete prostate cancer regressions in a Pten-deficient murine prostate cancer model and in human prostate cancer xenografts, indicating that both pathways coordinately support survival.
Journal ArticleDOI
Modulators of Prostate Cancer Cell Proliferation and Viability Identified by Short-Hairpin RNA Library Screening
Kimberly B. Dahlman,Joel S. Parker,Tambudzai Shamu,Haley Hieronymus,Caren Chapinski,Brett F Carver,Kenneth Chang,Gregory J. Hannon,Gregory J. Hannon,Charles L. Sawyers,Charles L. Sawyers +10 more
TL;DR: Recovery of hairpins targeting a known prostate cancer pathway validates the utility of shRNA library screening in prostate cancer as a broad strategy to identify new candidate drug targets.
Journal ArticleDOI
Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling
Jackie Wanjala,Barry S. Taylor,Caren Chapinski,Haley Hieronymus,John Wongvipat,Yu Chen,Gouri Nanjangud,Nikolaus Schultz,Yingqiu Xie,Shenji Liu,Wenfu Lu,Qing Yang,Chris Sander,Zhenbang Chen,Charles L. Sawyers,Brett S. Carver +15 more
TL;DR: The findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.